BACKGROUND: Studies of postmenopausal hormone therapy and lung cancer incidence have reported positive, negative, and null associations. Most of these studies, however, have had limited ability to control rigorously for cigarette smoking or to examine risk separately by smoking status. METHODS: We examined the association between postmenopausal hormone therapy and lung cancer incidence by smoking status among 72,772 women in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate rate ratios (RR). RESULTS: During follow-up from 1992 to 2003, we identified 659 cases of incident lung cancer. Current use of any postmenopausal hormone therapy was significantly associated with decreased risk of incident lung cancer [multivariate RR, 0.76; 95% confidence interval (95% CI), 0.62-0.92]. Similar risk estimates were observed for unopposed estrogen use (RR, 0.76; 95% CI, 0.60-0.94) and for estrogen plus progestin (RR, 0.76; 95% CI, 0.57-1.01). Risk associated with current use of postmenopausal hormone therapy was decreased among never smokers (RR, 0.56; 95% CI, 0.33-0.95) as well as current smokers (RR, 0.76; 95% CI, 0.55-1.05) and former smokers (RR, 0.76; 95% CI, 0.58-0.99). Former hormone use was not associated with lung cancer. No trend with duration of hormone use was detected. CONCLUSION: These results support the hypothesis that postmenopausal hormone therapy is associated with reduced risk of lung cancer, although the absence of a dose-response relationship weakens the evidence for causality.
BACKGROUND: Studies of postmenopausal hormone therapy and lung cancer incidence have reported positive, negative, and null associations. Most of these studies, however, have had limited ability to control rigorously for cigarette smoking or to examine risk separately by smoking status. METHODS: We examined the association between postmenopausal hormone therapy and lung cancer incidence by smoking status among 72,772 women in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate rate ratios (RR). RESULTS: During follow-up from 1992 to 2003, we identified 659 cases of incident lung cancer. Current use of any postmenopausal hormone therapy was significantly associated with decreased risk of incident lung cancer [multivariate RR, 0.76; 95% confidence interval (95% CI), 0.62-0.92]. Similar risk estimates were observed for unopposed estrogen use (RR, 0.76; 95% CI, 0.60-0.94) and for estrogen plus progestin (RR, 0.76; 95% CI, 0.57-1.01). Risk associated with current use of postmenopausal hormone therapy was decreased among never smokers (RR, 0.56; 95% CI, 0.33-0.95) as well as current smokers (RR, 0.76; 95% CI, 0.55-1.05) and former smokers (RR, 0.76; 95% CI, 0.58-0.99). Former hormone use was not associated with lung cancer. No trend with duration of hormone use was detected. CONCLUSION: These results support the hypothesis that postmenopausal hormone therapy is associated with reduced risk of lung cancer, although the absence of a dose-response relationship weakens the evidence for causality.
Authors: Cari L Meinhold; Amy Berrington de González; Elise D Bowman; Alina V Brenner; Raymond T Jones; James V Lacey; Christopher A Loffredo; Donna Perlmutter; Sara J Schonfeld; Glenwood E Trivers; Curtis C Harris Journal: Int J Cancer Date: 2011-03-15 Impact factor: 7.396
Authors: Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras Journal: Lung Cancer Manag Date: 2012-12
Authors: Louise A Brinton; Lauren Schwartz; Margaret R Spitz; Yikyung Park; Albert R Hollenbeck; Gretchen L Gierach Journal: Cancer Causes Control Date: 2012-02-25 Impact factor: 2.506
Authors: Christina S Baik; Gary M Strauss; Frank E Speizer; Diane Feskanich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-25 Impact factor: 4.254
Authors: Rowan T Chlebowski; Heather Wakelee; Mary Pettinger; Thomas Rohan; Jingmin Liu; Michael Simon; Hilary Tindle; Catherine Messina; Karen Johnson; Ann Schwartz; Margery Gass; Jean Wactawski-Wende Journal: Clin Lung Cancer Date: 2015-10-22 Impact factor: 4.785
Authors: Rowan T Chlebowski; Ann G Schwartz; Heather Wakelee; Garnet L Anderson; Marcia L Stefanick; JoAnn E Manson; Rebecca J Rodabough; Jason W Chien; Jean Wactawski-Wende; Margery Gass; Jane Morley Kotchen; Karen C Johnson; Mary Jo O'Sullivan; Judith K Ockene; Chu Chen; F Allan Hubbell Journal: Lancet Date: 2009-09-18 Impact factor: 79.321
Authors: Joshua R Smith; Elizabeth Barrett-Connor; Donna Kritz-Silverstein; Deborah L Wingard; Wael K Al-Delaimy Journal: Menopause Date: 2009 Sep-Oct Impact factor: 2.953